Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

co-diagnostics - CODX

CODX

Close Chg Chg %
1.04 0.00 0.00%

Open Market

1.04

0.00 (0.00%)

Volume: 8.52K

Last Updated:

Nov 21, 2024, 9:30 AM EDT

Trade Now

Company Overview: co-diagnostics - CODX

CODX Key Data

Open

$1.04

 Day Range

1.04 - 1.04

52 Week Range

1.00 - 2.23

 Market Cap

$33.21M

Shares Outstanding

31.93M

 Public Float

30.21M

Beta

-0.85

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.35

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

86.64K

  

CODX Performance

1 Week
 
 -1.89%
 
1 Month
 
 -15.45%
 
3 Months
 
 -40.57%
 
1 Year
 
 -7.96%
 
5 Years
 
 14.30%
 

CODX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About co-diagnostics - CODX

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

CODX At a Glance

Co-Diagnostics, Inc.
2401 South Foothill Drive
Salt Lake City, Utah 84109
Phone 1-801-438-1036 Revenue 991.47K
Industry Biotechnology Net Income -35,332,865.00
Sector Health Technology Employees 155
Fiscal Year-end 12 / 2024
View SEC Filings

CODX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 39.367
Price to Book Ratio 0.483
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.349
Enterprise Value to Sales -16.669
Total Debt to Enterprise Value -0.181

CODX Efficiency

Revenue/Employee 6,396.60
Income Per Employee -227,953.968
Receivables Turnover 2.996
Total Asset Turnover 0.009

CODX Liquidity

Current Ratio 10.812
Quick Ratio 10.522
Cash Ratio 10.187

CODX Profitability

Gross Margin -446.20
Operating Margin -4,894.415
Pretax Margin -3,843.832
Net Margin -3,563.674
Return on Assets -30.475
Return on Equity -35.239
Return on Total Capital -39.698
Return on Invested Capital -34.856

CODX Capital Structure

Total Debt to Total Equity 3.477
Total Debt to Total Capital 3.36
Total Debt to Total Assets 2.885
Long-Term Debt to Equity 2.502
Long-Term Debt to Total Capital 2.418
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Co-diagnostics - CODX

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
74.55M 97.89M 34.22M 991.47K
Sales Growth
+34,579.90% +31.30% -65.04% -97.10%
Cost of Goods Sold (COGS) incl D&A
16.73M 11.91M 6.76M 5.42M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
138.63K 335.36K 1.31M 1.23M
Depreciation
- 138.63K 335.36K 1.31M
Amortization of Intangibles
- - - -
-
COGS Growth
+9,281.32% -28.81% -43.21% -19.94%
Gross Income
57.82M 85.98M 27.45M (4.42M)
Gross Income Growth
+157,708.95% +48.69% -68.07% -116.11%
Gross Profit Margin
+77.56% +87.83% +80.23% -446.20%
2020 2021 2022 2023 5-year trend
SG&A Expense
16.13M 39.76M 39.05M 44.10M
Research & Development
3.19M 14.96M 17.44M 22.96M
Other SG&A
12.94M 24.80M 21.61M 21.14M
SGA Growth
+171.97% +146.51% -1.79% +12.95%
Other Operating Expense
- - - -
-
Unusual Expense
- - 151.00K 7.49M
-
EBIT after Unusual Expense
41.69M 46.06M (19.08M) (48.53M)
Non Operating Income/Expense
875.42K (429.16K) 232.96K 10.42M
Non-Operating Interest Income
97.22K 45.63K 704.04K 1.16M
Equity in Earnings of Affiliates
778.38K (430.43K) (332.97K) 100.70K
Interest Expense
- - - -
-
Interest Expense Growth
- - - -100.00%
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
42.57M 45.64M (18.85M) (38.11M)
Pretax Income Growth
+787.09% +7.20% -141.30% -102.21%
Pretax Margin
+57.10% +46.62% -55.08% -3,843.83%
Income Tax
90.54K 8.98M (4.61M) (2.78M)
Income Tax - Current - Domestic
637.76K 6.98M 297.57K 6.52M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(547.22K) 2.00M (4.91M) (9.30M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
778.38K (430.43K) (332.97K) 100.70K
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
42.48M 36.66M (14.24M) (35.33M)
Minority Interest Expense
- - - -
-
Net Income
42.48M 36.66M (14.24M) (35.33M)
Net Income Growth
+785.63% -13.70% -138.84% -148.15%
Net Margin Growth
+56.98% +37.45% -41.61% -3,563.67%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
42.48M 36.66M (14.24M) (35.33M)
Preferred Dividends
- - - -
-
Net Income Available to Common
42.48M 36.66M (14.24M) (35.33M)
EPS (Basic)
1.5898 1.2696 -0.4523 -1.204
EPS (Basic) Growth
+530.02% -20.14% -135.63% -166.20%
Basic Shares Outstanding
26.72M 28.87M 31.48M 29.35M
EPS (Diluted)
1.5171 1.2259 -0.4523 -1.204
EPS (Diluted) Growth
+510.36% -19.19% -136.90% -166.20%
Diluted Shares Outstanding
28.00M 29.90M 31.48M 29.35M
EBITDA
41.83M 46.55M (10.28M) (47.30M)
EBITDA Growth
+817.80% +11.28% -122.08% -360.16%
EBITDA Margin
+56.11% +47.56% -30.04% -4,770.31%

Snapshot

Average Recommendation HOLD Average Target Price 2.00
Number of Ratings 1 Current Quarters Estimate -0.34
FY Report Date 12 / 2024 Current Year's Estimate -1.22
Last Quarter’s Earnings -0.32 Median PE on CY Estimate N/A
Year Ago Earnings -1.204 Next Fiscal Year Estimate -1.17
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 1
Mean Estimate -0.34 -0.34 -1.22 -1.17
High Estimates -0.34 -0.34 -1.22 -1.17
Low Estimate -0.34 -0.34 -1.22 -1.17
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Co-diagnostics - CODX

Date Name Shares Transaction Value
May 29, 2024 Richard S. Serbin Director 117,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Richard S. Serbin Director 200,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 29, 2024 Dwight Howard Egan Chief Executive Officer; Director 409,214 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Dwight Howard Egan Chief Executive Officer; Director 367,206 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $1.09 per share 400,254.54
May 29, 2024 Dwight Howard Egan Chief Executive Officer; Director 627,500 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 29, 2024 James B. Nelson Director 115,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 James B. Nelson Director 200,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 29, 2024 Eugene Durenard Director 115,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Eugene Durenard Director 200,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 29, 2024 Edward L. Murphy Director 127,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Edward L. Murphy Director 200,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 29, 2024 Brian L. Brown Chief Financial Officer 326,554 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Brian L. Brown Chief Financial Officer 290,689 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $1.09 per share 316,851.01
May 29, 2024 Brian L. Brown Chief Financial Officer 515,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 30, 2024 Richard Abbott President 170,438 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Co-Diagnostics in the News